Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.
July 9, 2021Targovax announces resignation of Chief Financial Officer, Torbjørn Furuseth
July 2, 2021Targovax ASA issues options to new member of management
July 1, 2021Targovax ASA appoints Dr Lone Ottesen as Chief Development Officer
June 28, 2021Targovax to present at the 4th Annual Next Gen Immuno-Oncology Virtual Congress-US Edition